Zurich Cantonal Bank’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$68.7M Buy
88,871
+7,629
+9% +$5.84M 0.15% 122
2025
Q4
$62.7M Sell
81,242
-17,601
-18% -$12M 0.14% 134
2025
Q3
$55.6M Sell
98,843
-6,379
-6% -$3.61M 0.13% 133
2025
Q2
$55.2M Buy
105,222
+7,854
+8% +$4.38M 0.14% 129
2025
Q1
$61.8M Sell
97,368
-42,590
-30% -$29.3M 0.18% 101
2024
Q4
$99.7M Buy
139,958
+209
+0.1% +$175K 0.28% 59
2024
Q3
$147M Sell
139,749
-5,116
-4% -$5.69M 0.44% 35
2024
Q2
$152M Buy
144,865
+67,235
+87% +$65.2M 0.5% 29
2024
Q1
$74.7M Buy
77,630
+11,670
+18% +$11.1M 0.26% 69
2023
Q4
$57.9M Buy
65,960
+552
+0.8% +$455K 0.22% 86
2023
Q3
$53.8M Buy
65,408
+2,427
+4% +$1.91M 0.24% 79
2023
Q2
$45.3M Buy
62,981
+2,991
+5% +$2.31M 0.2% 100
2023
Q1
$49.3M Buy
59,990
+18,775
+46% +$14.2M 0.24% 84
2022
Q4
$29.7M Buy
41,215
+7,222
+21% +$5.33M 0.16% 132
2022
Q3
$23.4M Buy
33,993
+544
+2% +$342K 0.14% 141
2022
Q2
$19.8M Sell
33,449
-7,964
-19% -$5.18M 0.12% 164
2022
Q1
$28.9M Buy
41,413
+7,063
+21% +$4.47M 0.14% 133
2021
Q4
$21.7M Sell
34,350
-16,003
-32% -$9.84M 0.11% 176
2021
Q3
$30.5M Sell
50,353
-10,234
-17% -$6.35M 0.16% 116
2021
Q2
$33.8M Buy
60,587
+8,133
+16% +$4.12M 0.19% 104
2021
Q1
$24.8M Buy
52,454
+6,150
+13% +$2.99M 0.15% 135
2020
Q4
$22.4M Buy
46,304
+8,651
+23% +$4.67M 0.14% 146
2020
Q3
$21.1M Buy
37,653
+4,825
+15% +$2.93M 0.15% 125
2020
Q2
$20.5M Sell
32,828
-5,292
-14% -$3M 0.18% 109
2020
Q1
$18.6M Buy
38,120
+17,992
+89% +$7.42M 0.17% 118
2019
Q4
$7.56M Buy
20,128
+577
+3% +$194K 0.06% 347
2019
Q3
$5.42M Buy
19,551
+254
+1% +$75.2K 0.05% 394
2019
Q2
$6.04M Sell
19,297
-1,758
-8% -$585K 0.05% 379
2019
Q1
$8.65M Buy
21,055
+2,698
+15% +$1.11M 0.08% 286
2018
Q4
$6.86M Buy
18,357
+3,349
+22% +$1.23M 0.07% 304
2018
Q3
$6.06M Sell
15,008
-459
-3% -$175K 0.05% 378
2018
Q2
$5.34M Buy
15,467
+630
+4% +$197K 0.05% 408
2018
Q1
$5.11M Hold
14,837
0.05% 411
2017
Q4
$5.58M Sell
14,837
-3,117
-17% -$1.26M 0.05% 385
2017
Q3
$8.03M Buy
17,954
+1,596
+10% +$759K 0.07% 314
2017
Q2
$8.03M Sell
16,358
-1,298
-7% -$568K 0.08% 281
2017
Q1
$6.84M Sell
17,656
-1,666
-9% -$618K 0.07% 317
2016
Q4
$7.09M Buy
19,322
+2,821
+17% +$1.07M 0.07% 295
2016
Q3
$6.63M Buy
16,501
+8,896
+117% +$3.57M 0.07% 319
2016
Q2
$2.66M Buy
7,605
+500
+7% +$193K 0.03% 465
2016
Q1
$2.56M Buy
7,105
+241
+4% +$99.3K 0.03% 478
2015
Q4
$3.73M Sell
6,864
-1,154
-14% -$625K 0.05% 383
2015
Q3
$3.73M Buy
8,018
+568
+8% +$305K 0.05% 354
2015
Q2
$3.8M Buy
7,450
+2,330
+46% +$1.14M 0.05% 355
2015
Q1
$2.31M Buy
5,120
+228
+5% +$96.6K 0.03% 476
2014
Q4
$2.01M Sell
4,892
-438
-8% -$172K 0.06% 379
2014
Q3
$1.92M Sell
5,330
-35,101
-87% -$11.8M 0.06% 363
2014
Q2
$11.4M Buy
40,431
+7,731
+24% +$2.29M 0.34% 58
2014
Q1
$9.82M Sell
32,700
-2,376
-7% -$732K 0.3% 66
2013
Q4
$9.65M Sell
35,076
-1,170
-3% -$337K 0.32% 68
2013
Q3
$11.3M Sell
36,246
-25,413
-41% -$6.68M 0.39% 50
2013
Q2
$13.9M Buy
+61,659
New +$14.4M 0.48% 37

Other funds holding REGN

Zurich Cantonal Bank's REGN Position: Q1 2026 in Review

Zurich Cantonal Bank increased its Regeneron Pharmaceuticals (REGN) stake by 9.4% in Q1 2026, buying an estimated $5.84M and bringing the position to 88,871 shares worth $68.7M. The position accounts for 0.15% of the portfolio, ranked #122.

Zurich Cantonal Bank first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $152M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Zurich Cantonal Bank held 88,871 shares of Regeneron Pharmaceuticals worth $68.7M as of Q1 2026.
  • Zurich Cantonal Bank bought 7,629 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $5.84M.
  • Regeneron Pharmaceuticals made up 0.15% of Zurich Cantonal Bank's portfolio in Q1 2026, its #122 holding.
  • Zurich Cantonal Bank first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Zurich Cantonal Bank's Regeneron Pharmaceuticals position peaked at $152M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.